Phathom Pharmaceuticals Hits Day Low of $10.91 Amid Price Pressure

Phathom Pharmaceuticals, Inc. experienced significant volatility on July 13, 2026, with the stock declining by 13.44% and reaching an intraday low of USD 10.91. This performance starkly contrasts with the S&P 500, which saw a modest decline of 0.79% on the same day. Over the past week, Phathom's stock has decreased by 4.09%, while it has shown a positive trend over the past month with a gain of 5.26%. Despite the recent downturn, Phathom Pharmaceuticals has reported positive results in its financial performance, including a notable 104.43% growth in net sales. The company has consistently declared positive results for the last five quarters, highlighting its operational resilience. However, the stock's long-term fundamentals appear weak, with a negative book value and a poor EBIT to interest ratio of -11.11, indicating challenges in servicing its debt. Phathom's market capitalization stands at USD 834 million, and it has a high institutional ownership of 100%, suggesting that institutional investors are closely monitoring its performance. The company operates within the pharmaceuticals and biotechnology sector, which is characterized by its inherent risks and volatility.